Table of Contents

1 Product Introduction and Overview

• 1.1 Product Definition
• 1.2 Product Specification
• 1.3 Global Market Overview
  • 1.3.1 Global Radioimmunotherapy Market Status and Forecast (2016-2027)
  • 1.3.2 Global Radioimmunotherapy Sales Value CAGR by Region
• 1.4 Market Drivers, Inhibitors
  • 1.4.1 Market Drivers
  • 1.4.2 Market Inhibitors
  • 1.4.3 COVID-19 Impact Analysis

2 Global Radioimmunotherapy Supply by Company

• 2.1 Global Radioimmunotherapy Sales Value by Company
• 2.2 Radioimmunotherapy Sales Area of Main Manufacturers
• 2.3 Trend of Concentration Rate

3 Global and Regional Radioimmunotherapy Market Status by Category

• 3.1 Radioimmunotherapy Category Introduction
  • 3.1.1 Non Hodgkin Lymphoma (NHL)
  • 3.1.2 Follicular Lymphoma
  • 3.1.3 Solid Tumors
  • 3.1.4 Breast Cancer
  • 3.1.5 Ovarian Cancer
  • 3.1.6 Osteosarcoma
  • 3.1.7 Neuroblastoma
  • 3.1.8 Prostate Cancer
• 3.2 Global Radioimmunotherapy Market by Category
• 3.3 North America: by Category
• 3.4 Europe: by Category
• 3.5 Asia Pacific: by Category
• 3.6 Central & South America: by Category
• 3.7 Middle East & Africa: by Category

4 Global and Regional Radioimmunotherapy Market Status by End User/Segment

• 4.1 Radioimmunotherapy Segment by End User/Segment
  • 4.1.1 Tumor Antigens
  • 4.1.2 Radionuclides
  • 4.1.3 Antibodies
• 4.2 Global Radioimmunotherapy Market by End User/Segment
• 4.3 North America: by End User/Segment
• 4.4 Europe: by End User/Segment
• 4.5 Asia Pacific: by End User/Segment
• 4.6 Central & South America: by End User/Segment
• 4.7 Middle East & Africa: by End User/Segment

5 Global Radioimmunotherapy Market Status by Region

• 5.1 Global Radioimmunotherapy Market by Region
• 5.2 North America Radioimmunotherapy Market Status
• 5.3 Europe Radioimmunotherapy Market Status
• 5.4 Asia Pacific Radioimmunotherapy Market Status
• 5.5 Central & South America Radioimmunotherapy Market Status
• 5.6 Middle East & Africa Radioimmunotherapy Market Status

6 North America Radioimmunotherapy Market Status

• 6.1 North America Radioimmunotherapy Market by Country
• 6.2 United States
• 6.3 Canada
• 6.4 Mexico

7 Europe Radioimmunotherapy Market Status

• 7.1 Europe Radioimmunotherapy Market by Country
• 7.2 Germany
• 7.3 France
• 7.4 UK
• 7.5 Italy
• 7.6 Russia
• 7.7 Spain

8 Asia Pacific Radioimmunotherapy Market Status

• 8.1 Asia Pacific Radioimmunotherapy Market by Country
• 8.2 China
• 8.3 Japan
• 8.4 Korea
• 8.5 Southeast Asia
• 8.6 India
• 8.7 Australasia

9 Central & South America Radioimmunotherapy Market Status

• 9.1 Central & South America Radioimmunotherapy Market by Country
• 9.2 Brazil
• 9.3 Argentina
• 9.4 Colombia

10 Middle East & Africa Radioimmunotherapy Market Status

• 10.1 Middle East & Africa Radioimmunotherapy Market by Country
• 10.2 Iran
• 10.3 Israel
• 10.4 Turkey
• 10.5 South Africa
• 10.8 Saudi Arabia

11 Major Downstream Customers Analysis

• 11.1 Customer One Analysis
• 11.2 Customer Two Analysis
• 11.3 Customer Three Analysis
• 11.4 Customer Four Analysis

12 Global Radioimmunotherapy Market Forecast by Category and by End User/Segment

• 12.1 Global Radioimmunotherapy Sales Value Forecast (2022-2027)
• 12.2 Global Radioimmunotherapy Forecast by Category
• 12.3 Global Radioimmunotherapy Forecast by End User/Segment

13 Global Radioimmunotherapy Market Forecast by Region/Country

• 13.1 Global Radioimmunotherapy Market Forecast by Region (2022-2027)
• 13.2 North America Market Forecast
• 13.3 Europe Market Forecast
• 13.4 Asia Pacific Market Forecast
• 13.5 Central & South America Market Forecast
• 13.6 Middle East & Africa Market Forecast

14 Key Participants Company Information

• 14.1 Telix Pharmaceuticals
  • 14.1.1 Company Information
  • 14.1.2 Radioimmunotherapy Product Introduction
  • 14.1.3 Telix Pharmaceuticals Radioimmunotherapy Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.1.4 SWOT Analysis
• 14.2 Stella Pharma
  • 14.2.1 Company Information
  • 14.2.2 Radioimmunotherapy Product Introduction
  • 14.2.3 Stella Pharma Radioimmunotherapy Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.2.4 SWOT Analysis
• 14.3 RadioMedix
  • 14.3.1 Company Information
  • 14.3.2 Radioimmunotherapy Product Introduction
  • 14.3.3 RadioMedix Radioimmunotherapy Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.3.4 SWOT Analysis
• 14.4 Philogen
  • 14.4.1 Company Information
  • 14.4.2 Radioimmunotherapy Product Introduction
  • 14.4.3 Philogen Radioimmunotherapy Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.4.4 SWOT Analysis
• 14.5 PDL Biopharma
  • 14.5.1 Company Information
  • 14.5.2 Radioimmunotherapy Product Introduction
  • 14.5.3 PDL Biopharma Radioimmunotherapy Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.5.4 SWOT Analysis
• 14.6 Nordic Nanovector
  • 14.6.1 Company Information
  • 14.6.2 Radioimmunotherapy Product Introduction
  • 14.6.3 Nordic Nanovector Radioimmunotherapy Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.6.4 SWOT Analysis
• 14.7 Molecular Insight Pharmaceuticals
  • 14.7.1 Company Information
  • 14.7.2 Radioimmunotherapy Product Introduction
  • 14.7.3 Molecular Insight Pharmaceuticals Radioimmunotherapy Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.7.4 SWOT Analysis
• 14.8 Immunomedics
  • 14.8.1 Company Information
  • 14.8.2 Radioimmunotherapy Product Introduction
  • 14.8.3 Immunomedics Radioimmunotherapy Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.8.4 SWOT Analysis
• 14.9 Endocyte
  • 14.9.1 Company Information
  • 14.9.2 Radioimmunotherapy Product Introduction
  • 14.9.3 Endocyte Radioimmunotherapy Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.9.4 SWOT Analysis
• 14.10 Curasight
  • 14.10.1 Company Information
  • 14.10.2 Radioimmunotherapy Product Introduction
  • 14.10.3 Curasight Radioimmunotherapy Sales Value, Gross Margin and Global Share (2019-2021)
  • 14.10.4 SWOT Analysis
• 14.11 Clarity Pharmaceuticals
• 14.12 BioSynthema
• 14.13 Bayer Healthcare Pharmaceuticals

15 Conclusion

16 Methodology

Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global Radioimmunotherapy market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global Radioimmunotherapy market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.

Segmented by Category
Non Hodgkin Lymphoma (NHL)
Follicular Lymphoma
Solid Tumors
Breast Cancer
Ovarian Cancer
Osteosarcoma
Neuroblastoma
Prostate Cancer

Segmented by End User/Segment
Tumor Antigens
Radionuclides
Antibodies

Segmented by Country
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Spain
Asia Pacific
China
Japan
Korea
Southeast Asia
India
Australasia
Central & South America
Brazil
Argentina
Colombia
Middle East & Africa
Iran
Israel
Turkey
South Africa
Saudi Arabia

Key manufacturers included in this survey
Telix Pharmaceuticals
Stella Pharma
RadioMedix
Philogen
PDL Biopharma
Nordic Nanovector
Molecular Insight Pharmaceuticals
Immunomedics
Endocyte
Curasight
Clarity Pharmaceuticals
BioSynthema
Bayer Healthcare Pharmaceuticals